There are several CAR‐T cell trials targeting putative AML antigens including C‐type lectin‐like molecule‐1 (CLL‐1), CD33 and CD123,87 which if successful could also have activity in MPN, especially in patients with accelerated phase disease or post‐MPN AML. This evidence concerns the gene CD33 and myeloproliferative disorder.